Science that Strikes the Right Chord

Cabaletta Bio seeks to employ its Cabaletta Approach to B cell Ablation (CABA™) platform to develop T cell products to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.

How We Target Autoimmune Disease

Why “Cabaletta?"

A “cabaletta” is a rapid, repetitive, and technically challenging section of an operatic aria, designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development, building on our modular biologic platform that targets the driver of specific autoimmune diseases without the need for long-term immunosuppression.

Composing Cell Therapy Approaches in Autoimmunity

Composing Cell Therapy Approaches in Autoimmunity

Building on the established success of T cell therapies in cancer and recent compelling clinical data on CD19-CAR T in autoimmunity, we are developing Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) to address common and severe autoimmune diseases. CABA-201, our lead CARTA candidate, is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain, for B cell-mediated autoimmune diseases with high unmet need.

CABA-201

A Rapidly Expanding Collection of Targeted Cell Therapies

At Cabaletta, we are committed to transforming the treatment of autoimmune diseases by utilizing our innovative CABA™ platform to develop cell therapy products with the aim of providing deep, durable and potentially curative responses for patients with autoimmune diseases. In addition to our CARTA candidate, CABA-201, we are developing a pipeline of Chimeric AutoAntibody Receptor T (CAART) cells targeted to the cells responsible for autoantibody-mediated autoimmune diseases.

View Our Pipeline Posters & Publications

DSG3-CAART for Patients with Mucosal Pemphigus Vulgaris

Our lead CAART program, DSG3-CAART, is designed to specifically target B cells that express autoantibodies to the cell adhesion protein desmoglein 3 (DSG3), which cause mucosal pemphigus vulgaris (mPV), a rare and potentially deadly autoimmune blistering disease.

About DSG3-CAART

MuSK-CAART for Patients with MuSK-Associated Myasthenia Gravis

MuSK-CAART, our second CAART candidate, is designed to treat the subset of patients with MuSK-associated myasthenia gravis (MG) and targets B cells that express pathogenic autoantibodies against the MuSK protein, which is required for the formation and maintenance of the neuromuscular junction.

About MuSK-CAART

Putting Patients Center Stage

We’re on a mission to develop highly innovative and accessible cellular therapies with the potential to provide deep, durable, and potentially curative responses to patients by harnessing the power of the immune system. We aim to be their champions.

Our Focus: Patients

Our Crew: Developing Novel Treatments for Patients with Autoimmune Diseases

We are a clinical-stage biotechnology company working to develop and launch potentially breakthrough engineered T cell therapies for patients with autoimmune diseases.

About Us Our Collaborators Join Our Crew

Latest News

View All News

Email Alerts

Sign up for email alerts to stay informed and receive updates directly to your inbox.

Sign Up Today